Skip to main content

Table 2 NAT2 genotype frequencies and response to NTP treatment

From: Association of NAT2 genetic polymorphism with the efficacy of Neurotropin® for the enhancement of aggrecan gene expression in nucleus pulposus cells: a pilot study

Genotype N % b Phenotype NTP+ Nc NTP+ %d OR (95%CI) P value
Panel A        
 *4/*4 18 58.0 Rap 7 38.9 0.19 (0.04–0.95) 0.036
 *4/*5B 1 3.2 Int 1 100
 *4/*6A 6 19.4 Int 4 66.7 1.9 (0.28–11.98) 0.517
 *4/*7B 6 19.4 Int 5 83.3 5.4 (0.55–53.27) 0.118
 *4/*5B,*6A,*7B a 13 42.0 Int 10 76.9 5.2 (1.06–26.0) 0.036
Genotype in genders N %b Phenotype NTP+ Nc NTP+ %d OR (95%CI) P value
Panel B        
 Male *4/*4 9 29.0 Rap 2 22.2 0.1 (0.01–0.65) 0.012
 *4/*5B,*6A,*7Ba 10 32.3 Int 8 80.0 14.0 (1.54–127.2) 0.012
 Female *4/*4 9 29.0 Rap 5 55.5 0.6 (0.04–0.97) 0.735
 *4/*5B,*6A,*7Ba 3 9.7 Int 2 66.7 1.6 (0.10–24.7) 0.735
  1. Rap. Rapid, Int. intermediate
  2. aTotal of the variants
  3. bFrequency in the total sample
  4. cResponders to NTP treatment
  5. dFrequency of responders in each group